Ravi Pandey was awarded Ph.D. from the University of Rajasthan, Jaipur, India, under the supervision of Prof. B. C. Joshi. He was a postdoctoral fellow with Prof. K. M. Smith at the University of California, Davis, USA, and the late Prof. A. H. Jackson at the University College Cardiff, Wales. He then joined the Oncologic Foundation of Buffalo to work on a PDT project funded by Johnson & Johnson. In 1990, he joined the Roswell Park Comprehensive Cancer Center, Buffalo, where he is currently working as a Distinguished Professor of Oncology and the Director of Pharmaceutical Chemistry. His research focus is the development of multifunctional agents for cancer imaging (fluorescence, MRI, and PET) and therapy (PDT and SDT). He is also the Founder and CSO of Photolitec, LLC, a spin-off company of Roswell Park Cancer Institute. Photolitec was established in 2011 and has three products: HPPH (PDT for oesophageal cancer), Photobac (for the treatment of glioblastoma), and PET-ONCO (a PET imaging agent for bladder, kidney, prostate, pancreatic, and brain cancers), which are at various stages of human clinical trials.